CLX 0901
Latest Information Update: 25 Oct 2005
At a glance
- Originator Calyx Therapeutics (CEASED)
- Developer Pharma Bio-Research International
- Class Small molecules; Stilbenes
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 25 Oct 2005 Discontinued - Phase-II for Type-2 diabetes mellitus in Germany (PO)
- 25 Oct 2005 Discontinued - Phase-II for Type-2 diabetes mellitus in Netherlands (PO)
- 30 Mar 2001 Phase-II clinical trials for Type-2 diabetes mellitus in Germany (PO)